

Grifols, S.A. ("**Grifols**"), in accordance with the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, reports the following

OTHER RELEVANT INFORMATION

Following the article released earlier today in certain Spanish media regarding Grifols facing a potential lawsuit as a result of a claim for violating Donors' biometric identification rights in Illinois (U.S.), Grifols wishes to communicate that this case was properly disclosed in its audited consolidated financials for FY2021 and Half-Year 2022. It should be noted that the Court's recent order does nothing more than allow the plaintiffs' case to proceed, and therefore assumes for purposes of that order that the plaintiffs' allegations are true. However, there has not yet been any factual determination of the validity of those facts, and it is not a final determination. Grifols believes that it has meritorious defenses to the plaintiffs' claims.

Grifols has not recognized any provision for the claim in its financials due to its lack of materiality in accordance with the assessment performed by its legal advisors. In reaching this determination, the company has also considered other similar cases within the plasma industry, as well as the insurance coverage applicable.

In Barcelona, on 21 October 2022

Nuria Martín Barnés